CBO is looking for new research on the effectiveness of efforts to increase hepatitis C treatment, the costs of such treatment with direct-acting antiviral medications, and the costs of treating complications if the disease is untreated.
CBO describes its initial analysis of the potential federal budgetary effects of policies that would increase treatment of hepatitis C, focusing on two sample national policies that would increase treatment rates among Medicaid enrollees.
